Missouri
137–11
House passed a psilocybin research bill in 2026. It did not become law.
HB 1717 · 2026Arkansas · 2027 Legislative Session
Advancing Psilocybin Legislation in Arkansas
We're a group of concerned Arkansans working to pass legislation in 2027 that gives Arkansans access to therapeutic psilocybin.
Research-backed. Built for Arkansas.
72%
of U.S. voters back legal therapeutic access to psychedelics.
55%
say they or someone close to them has used psychedelics.
Source: UC Berkeley Psychedelics Survey, 2025 (n=1,577 U.S. voters), via Psychedelic Alpha.
Our neighbors are moving
It’s About Time.
States like ours are already acting on psychedelic therapy, often with broad bipartisan support.
Iowa
84–6
House passed a psilocybin production and administration bill in 2025.
HF 978 · 2025 voteLouisiana
Unanimous
Final votes for the 2026 psychedelic-assisted therapy research law.
SB 43 · Act 956 · 2026Texas
27–4
Senate adopted the final ibogaine research bill in 2025; enacted that June.
SB 2308 · 2025New Mexico
33–4
Senate passed the Medical Psilocybin Act; signed into law in April 2025.
SB 219 · 2025Oklahoma
69–21
House approved the final ibogaine clinical-trials bill; signed in May 2026.
HB 3834 · 2026
Selected legislative votes, 2025–2026. House passage alone does not mean a bill became law.
Other conservative, rural, veteran-heavy states are not sitting this out, and neither should we.
The evidence
What the research shows.
Researchers are studying psilocybin and other psychedelic-assisted therapies for conditions that affect Arkansas families. Explore the findings, the limits, and the work still underway.
Our board
The people behind this.
Physicians, clinicians, scientists, and public servants from across Arkansas.
Kemmi Sadler
Law Enforcement & Veteran Partnerships
“25 years in sworn law enforcement. Now I advocate for first responders.”
The 2027 bill
A careful, clinical path to access.
Draft · provisions not final
Our draft legislation, to be introduced in 2027, creates a regulated pathway for Arkansans to receive psilocybin therapy under qualified medical supervision.
Responsible access
Adults with qualifying conditions can access psilocybin therapy through licensed, regulated providers.
Clinical oversight
Treatment is screened, supervised, and documented by licensed healthcare professionals held to clear professional standards.
Patient protections
Safety standards, informed consent, and privacy safeguards protect every patient. [Specific provisions TBD]
Join the coalition
Add your name. Add your voice.
We're looking for concerned individuals and groups to review our initiatives, call their representatives, and sign on as official coalition members.
- Doctors
- Therapists
- Veterans
- First responders
- Patient advocates
- Researchers
- Healthcare workers
- Concerned citizens
Get legislative alerts.
Know when the bill moves and when your call matters most. A few messages per session, never spam.